Brokerages Set Cara Therapeutics, Inc. (NASDAQ:CARA) PT at $27.84

Cara Therapeutics, Inc. (NASDAQ:CARAGet Free Report) has been given an average recommendation of “Hold” by the five brokerages that are presently covering the firm, MarketBeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $27.84.

Separately, StockNews.com started coverage on Cara Therapeutics in a research report on Wednesday, January 8th. They issued a “sell” rating for the company.

Check Out Our Latest Report on Cara Therapeutics

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in CARA. Disciplined Growth Investors Inc. MN increased its stake in shares of Cara Therapeutics by 6.6% during the second quarter. Disciplined Growth Investors Inc. MN now owns 1,935,718 shares of the biopharmaceutical company’s stock worth $499,000 after purchasing an additional 120,660 shares in the last quarter. XTX Topco Ltd acquired a new stake in Cara Therapeutics in the 3rd quarter worth about $29,000. Finally, FMR LLC increased its stake in Cara Therapeutics by 18.5% during the 3rd quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock worth $65,000 after buying an additional 32,789 shares in the last quarter. 44.66% of the stock is currently owned by hedge funds and other institutional investors.

Cara Therapeutics Stock Up 18.4 %

Shares of NASDAQ:CARA opened at $5.99 on Friday. The firm has a 50 day moving average of $4.28 and a 200 day moving average of $3.95. The company has a market capitalization of $27.37 million, a price-to-earnings ratio of -0.29 and a beta of 0.51. Cara Therapeutics has a 52 week low of $2.71 and a 52 week high of $13.80.

Cara Therapeutics Company Profile

(Get Free Report

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.

Read More

Analyst Recommendations for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.